Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094724 | 0.87 | HTT (0.66) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL23996996 | 0.86 | S1PR1 (0.68) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL31506704 | 0.84 | ACHE (0.52) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL22324200 | 0.84 | ACHE (0.52) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL21938893 | 0.83 | ACHE (0.67) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL23997094 | 0.81 | ACHE (0.48) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL6498095 | 0.80 | ACHE (0.56) | SMN1; SMN2NPC1RAB9AS1PR1ACHE | |
| SCHEMBL431219 | 0.80 | S1PR1 (0.51) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL4039087 | 0.78 | ACHE (0.53) | SMN1; SMN2NPC1RAB9AS1PR1ACHE | |
| SCHEMBL6936347 | 0.78 | HTT (0.50) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575150-B2 | Triazole derivatives for treatment of Alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | SMN1; SMN2 2221/4885NPC1 162/4885RAB9A 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.